The global tardive dyskinesia therapeutics market size was estimated to be USD 3.59 billion in 2023 and is expected to reach at USD 9.56 billion by 2034 with a CAGR of 9.31% during the forecast period 2024-2034. Rising prevalence of tardive dyskinesia, surge in number of Schizophrenia patients, growing prevalence of neurological disorders such as Parkinson's, Alzheimer's, & Schizophrenia disease, high risk is associated with antipsychotic drugs, increasing prevalence of epilepsy, rising government awareness initiatives regarding the disease, surge in demand for novel treatment options, growing research & development activities for the formulation of new drugs, and increasing approval of innovative tardive dyskinesia therapeutics by regulatory bodies are some of the key factors boosting the market growth.
Increasing approval of innovative tardive dyskinesia therapeutics by regulatory bodies is predicted to boost the market growth during the forecast period. Tardive Dyskinesia (TD) is a condition characterized by involuntary movements of the tongue, face, trunk, and limbs, which is induced by long-term use of certain psychiatric medications, particularly antipsychotics. This disorder is most frequently observed in patients with conditions like schizophrenia, schizoaffective disorder, or bipolar disorder who have been prescribed antipsychotic medications for extended periods, although it can occasionally affect other individuals as well. While there is no known cure for TD, its symptoms can be managed with the use of two FDA-approved drugs: valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO). These medications fall into the VMAT2 inhibitor drug class (vesicular monoamine transporter-2 inhibitors) and are commonly used to treat movement disorders like Huntington's disease and tardive dyskinesia. For instance, in February 2023, Teva Pharmaceuticals has reported that the U.S. Food and Drug Administration (FDA) has given the green light to AUSTEDOXR (deutetrabenazine) extended-release tablets. This new formulation, designed for once-daily use, is intended for adults dealing with tardive dyskinesia (TD) and chorea linked to Huntington’s disease (HD).
By drug, valbenazine was the highest revenue-grossing segment in the global tardive dyskinesia therapeutics market in 2023 owing to the rising awareness initiatives regarding the diseases by market players and increasing approvals by regulatory bodies. For instance, In June 2023, Neurocrine Biosciences, Inc. has shared results from a meta-analysis of three extended-term studies assessing the effects of INGREZZA (valbenazine) capsules. These findings showed significant and consistent enhancements in tardive dyskinesia (TD) among adults, whether or not they were concurrently using antipsychotic therapy. Additionally, deutetrabenazine is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of neurological disorders and growing demand for the novel treatment options.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global tardive dyskinesia therapeutics market in 2023 owing to the increasing demand for obtaining therapeutics from hospital pharmacies, the regulatory systems in various countries tend to favor the prevalence of hospital pharmacies, and growing approvals by regulatory bodies. For instance, in March 2022, The Ministry of Health, Labor, and Welfare has officially approved Mitsubishi Tanabe Pharma Corporation's DYSVAL capsules 40mg for the treatment of tardive dyskinesia as a vesicular monoamine transporter type 2 (VMAT2) inhibitor. Additionally, drug stores & retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption for prescription refills and easy access to nearby retail pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing geriatric population, increasing prevalence of schizophrenia, surge in awareness, rising well-established healthcare infrastructure, and growing approvals by regulatory bodies. For instance, in September 2023, The Food and Drug Administration (FDA) has taken the step of reviewing the New Drug Application (NDA) for valbenazine oral granules, a novel sprinkle form of medication intended for adults dealing with tardive dyskinesia and those with chorea associated with Huntington's disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, rising healthcare expenditure, and increasing launch of novel treatments. For instance, in July 2023, Mitsubishi Tanabe Pharma Corporation, a part of the Mitsubishi Chemical Group, has disclosed that one of its group companies has introduced REMLEAS in Thailand for the treatment of tardive dyskinesia.
Increasing approval of innovative tardive dyskinesia therapeutics by regulatory bodies is predicted to boost the market growth during the forecast period. Tardive Dyskinesia (TD) is a condition characterized by involuntary movements of the tongue, face, trunk, and limbs, which is induced by long-term use of certain psychiatric medications, particularly antipsychotics. This disorder is most frequently observed in patients with conditions like schizophrenia, schizoaffective disorder, or bipolar disorder who have been prescribed antipsychotic medications for extended periods, although it can occasionally affect other individuals as well. While there is no known cure for TD, its symptoms can be managed with the use of two FDA-approved drugs: valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO). These medications fall into the VMAT2 inhibitor drug class (vesicular monoamine transporter-2 inhibitors) and are commonly used to treat movement disorders like Huntington's disease and tardive dyskinesia. For instance, in February 2023, Teva Pharmaceuticals has reported that the U.S. Food and Drug Administration (FDA) has given the green light to AUSTEDOXR (deutetrabenazine) extended-release tablets. This new formulation, designed for once-daily use, is intended for adults dealing with tardive dyskinesia (TD) and chorea linked to Huntington’s disease (HD).
By drug, valbenazine was the highest revenue-grossing segment in the global tardive dyskinesia therapeutics market in 2023 owing to the rising awareness initiatives regarding the diseases by market players and increasing approvals by regulatory bodies. For instance, In June 2023, Neurocrine Biosciences, Inc. has shared results from a meta-analysis of three extended-term studies assessing the effects of INGREZZA (valbenazine) capsules. These findings showed significant and consistent enhancements in tardive dyskinesia (TD) among adults, whether or not they were concurrently using antipsychotic therapy. Additionally, deutetrabenazine is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of neurological disorders and growing demand for the novel treatment options.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global tardive dyskinesia therapeutics market in 2023 owing to the increasing demand for obtaining therapeutics from hospital pharmacies, the regulatory systems in various countries tend to favor the prevalence of hospital pharmacies, and growing approvals by regulatory bodies. For instance, in March 2022, The Ministry of Health, Labor, and Welfare has officially approved Mitsubishi Tanabe Pharma Corporation's DYSVAL capsules 40mg for the treatment of tardive dyskinesia as a vesicular monoamine transporter type 2 (VMAT2) inhibitor. Additionally, drug stores & retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption for prescription refills and easy access to nearby retail pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing geriatric population, increasing prevalence of schizophrenia, surge in awareness, rising well-established healthcare infrastructure, and growing approvals by regulatory bodies. For instance, in September 2023, The Food and Drug Administration (FDA) has taken the step of reviewing the New Drug Application (NDA) for valbenazine oral granules, a novel sprinkle form of medication intended for adults dealing with tardive dyskinesia and those with chorea associated with Huntington's disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities, rising healthcare expenditure, and increasing launch of novel treatments. For instance, in July 2023, Mitsubishi Tanabe Pharma Corporation, a part of the Mitsubishi Chemical Group, has disclosed that one of its group companies has introduced REMLEAS in Thailand for the treatment of tardive dyskinesia.
Segmentation: Tardive Dyskinesia Therapeutics Market Report 2023 - 2034
Tardive Dyskinesia Therapeutics Market Analysis & Forecast by Drug 2023 - 2034 (Revenue USD Bn)
- Valbenazine
- Deutetrabenazine
- Others
Tardive Dyskinesia Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Online Pharmacies
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
Tardive Dyskinesia Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Tardive Dyskinesia Therapeutics Market: Drug Estimates & Trend Analysis
8. Tardive Dyskinesia Therapeutics Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Tardive Dyskinesia Therapeutics Market
11. Europe Global Tardive Dyskinesia Therapeutics Market
12. Asia Pacific Global Tardive Dyskinesia Therapeutics Market
13. Latin America Global Tardive Dyskinesia Therapeutics Market
14. MEA Global Tardive Dyskinesia Therapeutics Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Neurocrine Biosciences Inc
- Teva Pharmaceutical Industries Ltd
- Sanis
- Mitsubishi Tanabe Pharma Corporation
- AbbVie Inc.
- Adamas Pharmaceuticals Inc
- SteriMax Inc.
- Sun Pharmaceutical Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.59 Billion |
| Forecasted Market Value ( USD | $ 9.56 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
